Biopharmaceutical executives find that it has gotten more difficult to raise money than during the past few years when the market for initial public offerings was booming. As industry stock prices have fallen, investors have become more selective, but capital is available for attractive drug development programs.
Scrip’s Mandy Jackson spoke with six female biopharma executives in a roundtable discussion during the J.P. Morgan Healthcare Conference in...






